loader image
Monday, October 20, 2025
77.1 F
McAllen
- Advertisement -

New Genetic Marker Linked to Improved Survival with Immunotherapy in Ovarian & Other Cancers

Translate to Spanish or other 102 languages!

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without these mutations, according to researchers from The University of Texas MD Anderson Cancer Center. Image for illustration purposes
Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without these mutations, according to researchers from The University of Texas MD Anderson Cancer Center. Image for illustration purposes
- Advertisement -

By University of Texas MD Anderson Cancer Center 

Newswise — HOUSTON, JULY 2, 2025 ― Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without these mutations, according to researchers from The University of Texas MD Anderson Cancer Center.

Ovarian clear cell carcinoma is difficult to treat, and treatment options are limited 
Patients with specific PPP2R1A mutations in their tumors survived significantly longer after immunotherapy treatment 
Targeting PPP2R1A may improve responses even further according to laboratory studies  
PPP2R1A is an important predictive biomarker and possible treatment target for multiple cancer types, study found 

The findings, published in Nature, suggest PPP2R1A mutations could be a valuable biomarker to help guide treatment for this difficult-to-treat ovarian cancer subtype and may offer a new therapeutic target to further improve outcomes in multiple cancer types. 

- Advertisement -

Results of the study found that patients with PPP2R1A-mutant OCCC had a median overall survival (OS) of more than five years (66.9 months) after immunotherapy treatment, compared to just 9.2 months for patients without this mutation.  

Amir Jazaeri, M.D. Image Credit: The University of Texas MD Anderson Cancer Center via Newswise

“Developing effective immunotherapies for ovarian cancer, including rare subtypes like ovarian clear cell carcinoma, remains a significant unmet clinical need,” said co-senior author Amir Jazaeri, M.D., professor of Gynecologic Oncology and Reproductive Medicine. “Our study is the first to demonstrate the clinical importance of PPP2R1A mutations, and it opens the door to new strategies that could benefit many more patients.” 

In a Phase II trial, researchers investigated outcomes in a cohort of 34 patients with treatment-resistant OCCC who had been treated with a combination of immune checkpoint inhibitors – durvalumab and tremelimumab. Based on their findings in OCCC, experts also looked at two additional independent cohorts, one consisting of patients with endometrial cancer and the other including more than 9,000 patients with multiple cancer types who received immunotherapy treatment. Analyses confirmed the improved OS following immunotherapy in those with tumor PPP2R1A mutations.  

In parallel, laboratory research showed that targeting PPP2R1A both in vitro and in vivo was also associated with improved response to immunotherapy, suggesting a causal link. This too indicates that therapies targeting PPP2R1A and the associated protein phosphatase 2A (PP2A) molecular pathway could be added to immunotherapy to further boost outcomes.  

- Advertisement -

“Not only did we identify a new biomarker in ovarian cancer, but we also confirmed survival benefits in other cancer types,” Jazaeri said. “Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A pathway –using drugs, and we currently are evaluating this in a clinical trial at MD Anderson.” 

The study represents an ongoing collaboration across multiple disciplines, led by co-senior authors Jazaeri;Linghua Wang, M.D., Ph.D., associate professor of Genomic Medicine and associate member of the James P. Allison Institute and focus area co-lead with the Institute for Data Science in Oncology; and Rugang Zhang, Ph.D., chair of Experimental Therapeutics

This research was co-lead by first authors Yibo Dai and Minghao Dang, Ph.D., of the Wang laboratory; Anne Knisely, M.D., fellow in Gynecologic Oncology and Reproductive Medicine; and Mitsutake Yano, M.D., Ph.D., postdoctoral fellow in the Zhang laboratory. A full list of collaborating authors and their disclosures can be found in the paper.  

This study was supported through grants from the National Institutes of Health/National Cancer Institute (T32 CA101642, R01CA202919, R01CA239128, R01CA243142, R01CA260661, R01CA276569, P50CA281701 and P50CA272218, K07CA201013), Dunwoody-Reese Philanthropic, MD Anderson’s Ovarian Cancer Moon Shot, the U.S. Department of Defense (OC190181, OC210124, OC180193), the Cancer Prevention and Research Institute of Texas, Pennsylvania Department of Health CURE Funds, the Robert I. Jacobs Fund of The Philadelphia Foundation, the American Cancer Society (CA281701), and Frank McGraw Memorial Chair in Cancer Research.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Do Collagen Supplements Actually Work?

From powders to pills, collagen supplements promise youthful skin and strong hair – but do they actually work? 

The Human Bean’s “Coffee for a Cure” to Benefit The Renaissance Cancer Foundation, Oct. 17th

The Human Bean located at 1124 E. Nolana in McAllen is inviting coffee-lovers to "drink pink" on October 17 for their annual “Coffee for a Cure” breast cancer giveback event. All food and beverage proceeds on that day will benefit the Renaissance Cancer Foundation, marking The Human Bean’s largest fundraiser of the year.

2025 DHR Health Fashion Show & Gala Honoring Heroic Patients

The Edinburg Conference Center at Renaissance was filled with emotion, gratitude, and hope on Wednesday, October 15, 2025, as DHR Health hosted its 2025 Fashion Show & Gala Honoring Heroic Patients. The annual event celebrated breast cancer survivors and highlighted the importance of breast reconstruction awareness, education, and innovation in women’s health care.

The Harmful Effects of Alcohol on the Brain

Millions of people drink alcohol, and while many may know the harm it can cause to their liver, some may be surprised to know it can be just as damaging to the brain.
- Advertisement -
×